| HOME >> BIOLOGY >> TECHNOLOGY |
8,239,8357,917,267Earn-out liability payable in MiMedx common stock, net of current portion
-4,225,280Convertible Senior Secured Promissory Notes, net of unamortized
discount of $1,818,446 and $2,263,145, respectively, plus accrued
interest of$61,933 and $7,732, respectively
3,243,4872,744,587Other liabilities
320,055312,493Total liabilities
11,803,37715,199,627Commitments and contingencies (Note 12)
--Stockholders' equity:Preferred stock; $.001 par value; 5,000,000 shares authorized and 0
shares issued and outstanding
--Common stock; $.001 par value; 110,000,000 shares authorized;
81,052,359 issued and 81,002,359 outstanding for 2012 and
74,306,895 issued and 74,256,895 outstanding for 2011
81,05274,307Additional paid-in capital
79,471,32473,868,604Treasury stock (50,000 shares at cost)
(25,000)(25,000)Accumulated deficit
(63,859,067)(62,021,346)Total stockholders' equity
15,668,30911,896,565Total liabilities and stockholders' equity
$ 27,471,686$ 27,096,192See notes to condensed consolidated financial statementsMiMedx Group, Inc. and SubsidiariesNon-GAAP Financial Measures and ReconciliationAs used herein, "GAAP", refers to generally accepted accounting principles in the United States. We use various numerical measures in conference calls, investor meetings and other forums which are or may be considered "Non-GAAP financial measures" under Regulation G. We have provided below for your reference, supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.
Reconciliation of Net Loss to "Adjusted EBITDA" defined as Earnings before Interest, Taxes,
'/>"/>
| SOURCE MiMedx, Inc. Copyright©2012 PR Newswire. All rights reserved |